Glaucoma Market

DelveInsight’s ‘Glaucoma—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan. 


The Glaucoma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glaucoma market size from 2018 to 2030. The Report also covers current Glaucoma treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Glaucoma Disease Understanding and Treatment Algorithm

Glaucoma Overview

According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.


Open-angle glaucoma (OAG) is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This causes pressure in the eye to increase gradually and damages the optic nerve. It happens so slowly that the patient may lose vision before they are even aware of a problem, while in the case of narrow-angle glaucoma, the structure inside the eye that allows fluid to drain normally from the eye (called the drainage angle) becomes restricted. Narrow drainage angles in the eye increase the risk of the drainage angle that gets blocked, resulting in a significant increase in eye pressure and risk of vision loss. If this occurs, narrow-angle glaucoma is usually called angle-closure glaucoma.

Continued in the report…..


Glaucoma Diagnosis 

Although glaucoma is not a curable disease, early diagnosis and adequate treatment are effective in reducing or preventing further optic nerve (ON) damage. The difficulty of distinguishing between eyes without glaucoma and eyes with early or subtle glaucoma is widely acknowledged. Furthermore, there is no unanimous opinion on what constitutes the first signs of damage in glaucoma. 


1. Initial Glaucoma Evaluation

The initial glaucoma evaluation may include the tests and procedures of a comprehensive adult eye and vision examination in addition to some procedures specific to the differential diagnosis of glaucoma. Proper management of glaucoma requires a longitudinal evaluation of established baseline data for important clinical parameters. 

Continued in the report…..


Glaucoma Treatment 

Glaucoma is a group of eye diseases that can cause vision loss and blindness by damaging a nerve in the back of the eye called the optic nerve. 

There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery.  

Continued in the report…..

Glaucoma Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Glaucoma, Type-Specific Diagnosed Prevalent Population of Glaucoma, Gender-Specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.


Key Findings

  • The total diagnosed prevalent population of Glaucoma in the 7MM was 10,104,188 in 2020 , which is expected to increase in the forecast period (2021-2030). 
  • Among the European five countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,042,465 cases, followed by Italy and France in 2020. On the other hand, Spain had the lowest.  
  • Japan had 2,886,961 diagnosed prevalent cases for Glaucoma in 2020.


“As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries. The highest proportion of Gluacoma caseswas observed in 70-79 years age group in the US, while in the EU-5 countries, people aged ≥80 years accounted for the maximum patient pool. In contrast, middle age population aged 40-49 years contributed highest patient pool in Japan. Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases”.

Country-Wise Glaucoma Epidemiology 

The epidemiology segment also provides the Glaucoma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Glaucoma Drug Chapters


Glaucoma Emerging Drugs 


PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)

PDP-716 is a novel, once-a-day formulation of Brimonidine developed using SPARC’s TearActTM Technology for treatment of Glaucoma. The drug provides dosing convenience to patients compared to a currently marketed product that requires thrice-a-day dosing. The drug contains brimonidine which is one of the most commonly used treatments of glaucoma and ocular hypertension. 


SPARC has initiated the pivotal Phase III study of PDP-716 for registration in USA. The study is randomizing patients and is expected to be completed in FY21.


PRO-122: Laboratorios Sophia S.A de C.V.

PRO-122 is developed by Laboratories Sophia for the treatment of primary open-angle glaucoma (POAG) and it is effective in maintaining intraocular pressure. This drug is currently in Phase III clinical trial.

Products detail in the report…

List to be continued in the report…

Glaucoma Market Outlook

Glaucoma is an eye disease that gradually steals vision. There are typically no early warning signs or painful symptoms of glaucoma. It develops slowly and sometimes without noticeable sight loss for many years.


The damage caused by glaucoma cannot be reversed. But treatment and regular checkups can help slow or prevent vision loss, especially if the disease is in its early stages. Glaucoma is treated by lowering the eye pressure (intraocular pressure). Depending on the situation, the options may include prescription eye drops, oral medications, laser treatment, surgery or a combination of any of these.


Management of the disease focuses on lowering intraocular pressure (IOP) with the current class of drugs, like prostaglandin analogs, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors. However, these treatments have not helped all patients. Some patients continue to experience deterioration in the optic nerve even though their IOPs are within the normal range. Besides these pharmacological treatment measurements, incisional surgery, laser surgery, and medication are also preferred. 


There are several risk factors like age > 60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, and myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly. 


The main goal of glaucoma treatment is to increase the quality of life through the reduction of IOP to preserve visual function. In the process of IOP reduction, an ideal medication should have a schedule that is simple to follow, be least interrupting with a patient’s life, highly tolerable and affordable. However, the medical treatment of glaucoma has associated side effects, complications, and costs. 


Prostaglandins as a newer class of IOP-reducing agents have gained tremendous popularity in the management of glaucoma. Prostaglandins are biologically active derivatives of arachidonic acid with diverse local responses that are tissue-dependent. Arachidonic acid is bound to phospholipids in the membranes of most mammalian cells. The release of arachidonic acid is catalyzed by the enzyme phospholipase A2, and arachidonic acids are then converted into PGs by cyclooxygenase and PG synthetase. PGs are the most potent ocular hypotensive agents yet discovered. 


Multiple prostanoid receptors (e.g., DP, EP1 to EP4, FP, IP, and TP) have been identified based on studies using molecular biologic, second-messenger, radio-ligand binding, and functional techniques. In the United States, drugs of this class have been approved in the past few years like Vyzulta, Xelpros, and Travatan Z by the US FDA. 


After the Initial introduction of prostaglandins in the US in 1996, rapidly replaced topical beta-blockers as first-line IOP-lowering agents, mostly because of their potency, safe systemic side-effect profile, and once-daily dosing.


According to the (Glaucoma Research Foundation, n.d.), Prostaglandin analogs are the first treatment choice for many glaucoma patients. A comparative analysis was performed by (Li et al., 2016). In this comparative analysis, randomized controlled trials that compared a single active topical medication with no treatment/placebo or another single topical medication were included. This study concluded that all active first-line drugs are effective compared to placebo and prostaglandins that were more efficacious in lowering IOP at 3 months than beta-blockers, alpha agonists, or carbonic anhydrase. Bimatoprost, latanoprost, and travoprost are among the most efficacious drugs, although the within-class differences were small and may not be clinically meaningful.

Continued in the report…..


Key Findings

  • The market size of Glaucoma in the 7MM was estimated to be USD 3,796 million in 2020.
  • The approved therapies considered in the different class are as follows: Prostaglandin analogs: Latanoprost, Travoprost, Bimatoprost, Tafluprost, Latanoprostene Bunod; Beta Blockers: Timolol, Betaxolol; Carbonic anhydrase inhibitors: Dorzolamide, Brinzolamide; Mitotics: Pilocarpine; Alpha-2-selective adrenergic agonists: Brimonidine, Apraclonidine; Others: Osmotic diuretics (Mannitol and Glycerol).
  • Of this, in the 7MM the majority of the market share is accommodated by Prostaglandin analogs generating USD 1,664.2 million, followed by Carbonic anhydrase inhibitors generating USD 525.0 million while Miotics contributed the least towards the market share, with USD 135.3 million, in 2020.

  

“Since glaucoma is one the major cause of blindness, hence there is a pressing need for better understanding of pharmacology of the disease, causing the glaucoma pharmaceutical market to evolve. In the past few years, many drugs have been approved for glaucoma or open-angle glaucoma, and apart from that there are numerous pipeline products as well that are under development for Glaucoma. Products like, Vyzulta, Rhopressa/Rhokiinsa, Rocklatan/Roclanda, Xelpros, and DURYSTA (bimatoprost implant) are some of the potential latest approved products. Taking about there competition with each other, if we see, Vyzulta, Rhopressa/Rhokiinsa, and Rocklatan/Roclanda are all ophthalmic solution, whereas, DURYSTA first dissolvable implant approved for glaucoma.“


The United States Market Outlook

This section provides the total Glaucoma market size and; market size by therapies in the United States.


EU-5 Market Outlook

The total Glaucoma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook 

The total Glaucoma market size and market size by therapies in Japan are provided.

Glaucoma Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched in the market during the study period 2018–2030. The analysis covers the Glaucoma market uptake by drugs; patient uptake by therapies; and sales of each drug.  


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Glaucoma Development Activities 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyzes key players involved in developing targeted therapeutics. 


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Glaucoma emerging therapies. 

Reimbursement Scenario in Glaucoma


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

Competitive Intelligence Analysis 

We perform competitive and market Intelligence analysis of the Glaucoma market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.  

Scope of the Report

  • The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into the Glaucoma epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Glaucoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Glaucoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glaucoma market

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, effectiveness of drugs as both mono and combination therapy will positively drive the Glaucoma market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Glaucoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Glaucoma. The launch of emerging therapies will significantly impact the Glaucoma market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Glaucoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Glaucoma Pipeline Analysis
  • Glaucoma Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Glaucoma Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage 
  • Glaucoma Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake

Glaucoma Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Glaucoma market share (%) distribution in 2020 and how it would look like in 2030?
  • What would be the Glaucoma total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Glaucoma market size during the forecast period (2021–2030)?
  • At what CAGR, the Glaucoma market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the Glaucoma market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Glaucoma market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Glaucoma?
  • What is the historical Glaucoma patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Glaucoma at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glaucoma?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Glaucoma during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Glaucoma along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Glaucoma in the US and Europe?
  • What are the Glaucoma marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Glaucoma?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Glaucoma?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glaucoma therapies? 
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies? 
  • What are the clinical studies going on for Glaucoma and their status?
  • What are the key designations that have been granted for the emerging therapies for Glaucoma?
  • What are the 7MM historical and forecasted market of Glaucoma?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Glaucoma.
  • To understand the future market competition in the Glaucoma market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Glaucoma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Glaucoma market.
  • To understand the future market competition in the Glaucoma market.

1. Key Insights

2. Report Introduction

3. Glaucoma Market Overview at a Glance

3.1. Market Share (%) Distribution of Glaucoma in 2018

3.2. Market Share (%) Distribution of Glaucoma in 2030

4. Executive Summary of Glaucoma

5. Disease Background and Overview

5.1. Introduction

5.2. Classification of Glaucoma

5.2.1. Classification of Open-Angle Glaucoma (OAG)

5.2.2. Classification of Close-Angle Glaucoma/Angle-closure glaucoma (ACG)

5.3. Signs and Symptoms of Glaucoma

5.3.1. Signs and Symptoms of Open-Angle Glaucoma

5.3.2. Signs and Symptoms of Closed-angle Glaucoma

5.4. Risk Factors of Glaucoma

5.4.1. Risk Factors associated with Primary Open-angle Glaucoma (POAG)

5.4.1.1. General

5.4.1.2. Ocular

5.4.1.3. Nonocular

5.4.1.4. Ocular Hypertension

5.4.2. Risk Factors associated with Closed-angle Glaucoma

5.5. Genes Involved in Glaucoma

5.5.1. Primary Open Angle Glaucoma

5.5.2. Primary Closed Angle Glaucoma (PACG)

5.6. Diagnosis

5.6.1. Diagnosis of Glaucoma

5.6.2. Diagnostic criteria of Angle Closure Glaucoma

5.6.3. Differential Diagnosis of Glaucoma

5.6.4. Diagnostic Algorithm for Glaucoma

5.6.5. Primary Glaucoma Preferred Practice Pattern guidelines

6. Treatment Algorithm for Open-Angle Glaucoma

7. Treatment for Glaucoma

7.1. Medicines

7.1.1. Beta-Blockers:

7.1.2. Prostaglandin Analogs:

7.1.3. Alpha-adrenergic agonists:

7.1.4. Carbonic Anhydrase Inhibitors:

7.2. Laser treatment

7.3. Surgery

7.4. Treatment of Primary Open-angle Glaucoma

7.4.1. Selective Laser Trabeculoplasty (SLT)

7.4.2. Medications

7.5. Treatment for Angle-closure glaucoma (ACG)

7.6. Treatment Guidelines

7.6.1. International Council of Ophthalmology Guidelines for Glaucoma Eye Care

7.6.2. Level of evidence and recommendation in medical treatment of PACG.

7.6.3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation

7.6.6. Primary Open-angle Glaucoma Preferred Practice Pattern guidelines

8. Epidemiology and Patient Population

8.1. Key Findings

8.2. Epidemiology Methodology

8.3. Total Diagnosed Prevalence of Glaucoma in the 7MM

8.4. Epidemiology of Glaucoma

8.5. The United States

8.5.1. Total Diagnosed Prevalence of Glaucoma in the United States

8.5.2. Type-specific Diagnosed Prevalent Population of Glaucoma in the United States

8.5.3. Gender-specific Diagnosed Prevalence of Glaucoma in the United States

8.5.4. Age-specific Diagnosed Prevalence of Glaucoma in the United States

8.5.5. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States

8.6. EU5

8.6.1. Germany

8.6.1.1. Total Diagnosed Prevalence of Glaucoma in Germany

8.6.1.2. Type-specific Diagnosed Prevalent Population of Glaucoma in Germany

8.6.1.3. Gender-specific Diagnosed Prevalence of Glaucoma in Germany

8.6.1.4. Age-specific Diagnosed Prevalence of Glaucoma in Germany

8.6.1.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany

8.6.2. France

8.6.2.1. Total Diagnosed Prevalence of Glaucoma in France

8.6.2.2. Type-specific Diagnosed Prevalent Population of Glaucoma in France

8.6.2.3. Gender-specific Diagnosed Prevalence of Glaucoma in France

8.6.2.4. Age-specific Diagnosed Prevalence of Glaucoma in France

8.6.2.5. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France

8.6.3. Italy

8.6.3.1. Total Diagnosed Prevalence of Glaucoma in Italy

8.6.3.2. Type-specific Diagnosed Prevalent Population of Glaucoma in Italy

8.6.3.3. Gender-specific Diagnosed Prevalence of Glaucoma in Italy

8.6.3.4. Age-specific Diagnosed Prevalence of Glaucoma in Italy

8.6.3.5. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy

8.6.4. Spain

8.6.4.1. Total Diagnosed Prevalence of Glaucoma in Spain

8.6.4.2. Type-specific Diagnosed Prevalent Population of Glaucoma in Spain

8.6.4.3. Gender-specific Diagnosed Prevalence of Glaucoma in Spain

8.6.4.4. Age-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain

8.6.4.5. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain

8.6.5. United Kingdom

8.6.5.1. Total Diagnosed Prevalence of Glaucoma in the United Kingdom

8.6.5.2. Type-specific Diagnosed Prevalent Population of Glaucoma in the United Kingdom

8.6.5.3. Gender-specific Diagnosed Prevalence of Glaucoma in the United Kingdom

8.6.5.4. Age-specific Diagnosed Prevalence of Glaucoma in the United Kingdom

8.6.5.5. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United Kingdom

8.7. Japan

8.7.1. Total Diagnosed Prevalence of Glaucoma in Japan

8.7.2. Type-specific Diagnosed Prevalent Population of Glaucoma in Japan

8.7.3. Gender-specific Diagnosed Prevalence of Glaucoma in Japan

8.7.4. Age-specific Diagnosed Prevalence of Glaucoma in Japan

8.7.5. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan

9. Organizations contributing towards Open-Angle Glaucoma (OAG)

10. Patient Journey

11. Case Reports

12. Marketed Products

12.1. Key Cross

12.2. Rocklatan: Aerie Pharmaceuticals

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Clinical Development

12.2.3.1. Clinical Trials Information

12.2.4. Safety and efficacy

12.2.5. Product Profile

12.3. Rhopressa: Aerie Pharmaceuticals

12.3.1. Product Description

12.3.2. Regulatory Milestones

12.3.3. Clinical Development

12.3.3.1. Clinical Trials Information

12.3.4. Safety and efficacy

12.3.5. Product Profile

12.4. Xelpros (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited

12.4.1. Product Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.4. Safety and efficacy

12.4.5. Product Profile

12.5. Eybelis Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries

12.5.1. Product Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.3.1. Clinical Trials Information

12.5.4. Safety and efficacy

12.5.5. Product Profile

12.6. Vyzulta: Bausch and Lomb

12.6.1. Product Description

12.6.2. Regulatory Milestones

12.6.3. Clinical Development

12.6.3.1. Clinical Trials Information

12.6.4. Safety and efficacy

12.6.5. Product Profile

12.7. Tapcom/DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Clinical Development

12.7.3.1. Clinical Trials Information

12.7.4. Safety and efficacy

12.7.5. Product Profile

12.8. Glanatec: D.Western Therapeutics Institute (DWTI)/Kowa LTD.

12.8.1. Product Description

12.8.2. Regulatory Milestones

12.8.3. Clinical Development

12.8.3.1. Clinical Trials Information

12.8.4. Safety and Efficacy

12.8.5. Product Profile

12.9. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon Research

12.9.1. Product Description

12.9.2. Regulatory Milestones

12.9.3. Clinical Development

12.9.3.1. Clinical Trials Information

12.9.4. Safety and efficacy

12.9.5. Product Profile

12.10. Zioptan (tafluprost): Merck Sharp & Dohme Corp.

12.10.1. Product Description

12.10.2. Regulatory Milestones

12.10.3. Clinical Development

12.10.3.1. Clinical Trials Information

12.10.4. Product Profile

12.11. DuoTrav PQ (travoprost/timolol): Novartis/Alcon Research

12.11.1. Product Description

12.11.2. Regulatory Milestones

12.11.3. Clinical Development

12.11.3.1. Clinical Trials Information

12.11.4. Safety and efficacy

12.11.5. Product Profile

12.12. Travatan Z (travoprost ophthalmic solution) 0.004%: Alcon Research, a Novartis company

12.12.1. Product Description

12.12.2. Regulatory Milestones

12.12.3. Clinical Development

12.12.3.1. Clinical Trials Information

12.12.4. Safety and efficacy

12.12.5. Product Profile

12.13. Lumigan 0.01% (bimatoprost ophthalmic solution): Allergan

12.13.1. Product Description

12.13.2. Regulatory Milestones

12.13.3. Clinical Development

12.13.3.1. Clinical Trials Information

12.13.4. Safety and efficacy

12.13.5. Product Profile

12.14. Durysta (Bimatoprost SR): Allergan

12.14.1. Product Description

12.14.2. Regulatory Milestones

12.14.3. Clinical Development

12.14.3.1. Clinical Trials Information

12.14.4. Safety and efficacy

12.14.5. Product Profile

12.15. AILAMIDE: Senju Pharmaceuticals

12.15.1. Product Description

12.15.2. Mechanism of action

12.15.3. Regulatory Milestones

12.15.4. Clinical Development

12.15.5. Product Profile

12.16. Aibeta: Senju Pharmaceuticals

12.16.1. Product Description

12.16.2. Regulatory Milestones

12.16.3. Product Profile

13. Emerging Therapies

13.1. Key Cross

13.2. PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)

13.2.1. Drug Description

13.2.2. Other Developmental Activities

13.2.3. Clinical Development

13.2.4. Clinical Trials Information

13.2.5. Safety and Efficacy

13.2.6. Product Profile

13.3. PRO-122: Laboratorios Sophia S.A de C.V.

13.3.1. Drug Description

13.3.2. Clinical Development

13.3.3. Clinical Trials Information

13.3.4. Safety and Efficacy

13.3.5. Product Profile

13.4. Brinzolamide Ophthalmic Suspension 1%: Perrigo Company

13.4.1. Drug Description

13.4.2. Clinical Development

13.4.3. Clinical Trials Information

13.4.4. Product Profile

13.5. DE-130A (Catioprost): Santen Pharmaceutical

13.5.1. Drug Description

13.5.2. Clinical Development

13.5.3. Clinical Trials Information

13.5.4. Product Profile

13.6. Sepetaprost (DE-126/ONO-9054): Santen Inc./Ono Pharmaceutical

13.6.1. Drug Description

13.6.2. Other Developmental Activities

13.6.3. Clinical Development

13.6.4. Clinical Trials Information

13.6.5. Safety and Efficacy

13.6.6. Product Profile

13.7. NCX 470: Nicox Ophthalmics

13.7.1. Drug Description

13.7.2. Other Developmental Activities

13.7.3. Clinical Development

13.7.4. Clinical Trials Information

13.7.5. Safety and Efficacy

13.7.6. Product Profile

13.8. Bamosiran (SYL040012): Sylentis

13.8.1. Drug Description

13.8.2. Other Developmental Activities

13.8.3. Clinical Development

13.8.4. Clinical Trials Information

13.8.5. Safety and Efficacy

13.8.6. Product Profile

13.9. ENV515 (Travoprost XR): Envisia Therapeutics

13.9.1. Drug Description

13.9.2. Other Developmental Activities

13.9.3. Clinical Development

13.9.4. Clinical Trials Information

13.9.5. Safety and Efficacy

13.9.6. Product Profile

13.10. Nyxol (Phentolamine Mesylate): Ocuphire Pharma

13.10.1. Drug Description

13.10.2. Other Developmental Activities

13.10.3. Clinical Development

13.10.4. Clinical Trials Information

13.10.5. Safety and Efficacy

13.10.6. Product Profile

13.11. Ripasudil hydrochloride hydrate/Brimonidine tartrate (K-232): Kowa Company/D.Western Therapeutics Institute

13.11.1. Drug Description

13.11.2. Other Developmental Activities

13.11.3. Clinical Development

13.11.4. Clinical Trials Information

13.11.5. Product Profile

13.12. POLAT-001: Peregrine Ophthalmic

13.12.1. Drug Description

13.12.2. Other Developmental Activities

13.12.3. Clinical Development

13.12.4. Clinical Trials Information

13.12.5. Product Profile

14. Glaucoma: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Methodology

14.3. Market Size of Glaucoma in the 7MM in USD Million (2018–2030)

14.4. Market Size of Glaucoma by Therapies in the 7MM

14.5. Market Outlook

14.6. Attribute Analysis

14.7. Key Market Forecast Assumptions

14.8. United States Market Size

14.8.1. Total Market Size of Glaucoma in the United States

14.8.2. Market Size of Glaucoma by Therapies in the United States

14.9. EU-5 Market Size

14.9.1. Germany

14.9.1.1. Total Market size of Glaucoma in Germany

14.9.1.2. Market Size of Glaucoma by Therapies in Germany

14.9.2. France

14.9.2.1. Total Market size of Glaucoma in France

14.9.2.2. Market Size of Glaucoma by Therapies in France

14.9.3. Italy

14.9.3.1. Total Market size of Glaucoma in Italy

14.9.3.2. Market Size of Glaucoma by Therapies in Italy

14.9.4. Spain

14.9.4.1. Total Market size of Glaucoma in Spain

14.9.4.2. Market Size of Glaucoma by Therapies in Spain

14.9.5. United Kingdom

14.9.5.1. Total Market size of Glaucoma in the United Kingdom

14.9.5.2. Market Size of Glaucoma by Therapies in the United Kingdom

14.10. Japan

14.10.1. Total Market size of Glaucoma in Japan

14.10.2. Market Size of Glaucoma by Therapies in Japan

15. KOL Views

16. Market Drivers

17. Market Barriers

18. SWOT Analysis

19. Unmet Needs

20. Reimbursement

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

List of Table

Table 1: Summary of Glaucoma Market, Epidemiology, and Key Events (2018–2030)

Table 2: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations

Table 3: Genes associated with the risk of POAG

Table 4: Genes identified in linkage or association with PACG

Table 5: Differential Diagnosis for Glaucoma

Table 6: The definitions and levels of evidence to rate individual studies

Table 7: Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE

Table 8: Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines

Table 9: Primary Closed-Angle Glaucoma Preferred Practice Pattern guidelines

Table 10: Initiating Open-angle Glaucoma Care – International Recommendations

Table 11: Medicines for Glaucoma Care: International Recommendations

Table 12: Initiating Closed-angle Care – International Recommendations

Table 13: Unstable Closed-angle Glaucoma – International Recommendations

Table 14: Level of evidence and recommendation in medical treatment of PACG

Table 15: Level of evidence and recommendation in treatment laser Del PACG

Table 16: Level of evidence and recommendation in the surgical treatment of PACG

Table 17: Total Diagnosed Prevalence of Glaucoma in the 7MM (2018–2030)

Table 18: Total Diagnosed Prevalence of Glaucoma in the United States (2018–2030)

Table 19: Type-specific Diagnosed Prevalent Population of Glaucoma in the US (2018–2030)

Table 20: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2018–2030)

Table 21: Age-specific Diagnosed Prevalence of Glaucoma in the United States (2018–2030)

Table 22: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the United States (2018–2030)

Table 23: Total Diagnosed Prevalence of Glaucoma in Germany (2018–2030)

Table 24: Type-specific Diagnosed Prevalent Population of Glaucoma in Germany (2018–2030)

Table 25: Gender-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)

Table 26: Age-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)

Table 27: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2018–2030)

Table 28: Total Diagnosed Prevalence of Glaucoma in France (2018–2030)

Table 29: Type-specific Diagnosed Prevalent Population of Glaucoma in France (2018–2030)

Table 30: Gender-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)

Table 31: Age-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)

Table 32: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2018–2030)

Table 33: Total Diagnosed Prevalence of Glaucoma in Italy (2018–2030)

Table 34: Type-specific Diagnosed Prevalent Population of Glaucoma in Italy (2018–2030)

Table 35: Gender-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)

Table 36: Age-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)

Table 37: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2018–2030)

Table 38: Total Diagnosed Prevalence of Glaucoma in Spain (2018–2030)

Table 39: Type-specific Diagnosed Prevalent Population of Glaucoma in Spain (2018–2030)

Table 40: Gender-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)

Table 41: Age-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)

Table 42: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2018–2030)

Table 43: Total Diagnosed Prevalence of Glaucoma in the UK (2018–2030)

Table 44: Type-specific Diagnosed Prevalent Population of Glaucoma in the UK (2018–2030)

Table 45: Gender-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)

Table 46: Age-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)

Table 47: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the UK (2018–2030)

Table 48: Total Diagnosed Prevalence of Glaucoma in Japan (2018–2030)

Table 49: Type-specific Diagnosed Prevalent Population of Glaucoma in Japan (2018–2030)

Table 50: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)

Table 51: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)

Table 52: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2018–2030)

Table 53: Organizations contributing toward the fight against Glaucoma

Table 54: List of Marketed Drugs and their Relative Therapeutic Classes

Table 55: Rockland, Clinical Trial Description, 2021

Table 56: Rhopressa, Clinical Trial Description, 2021

Table 57: Eybelis Ophthalmic Solution 0.002%, Clinical Trial Description, 2021

Table 58: Vyzulta, Clinical Trial Description, 2021

Table 59: DE-111; Clinical Trial Description, 2021

Table 60: Glanatec, Clinical Trial Description, 2021

Table 61: Simbrinza, Clinical Trial Description, 2021

Table 62: Zioptan, Clinical Trial Description, 2021

Table 63: DuoTrav, Clinical Trial Description, 2021

Table 64: Travatan Z, Clinical Trial Description, 2021

Table 65: Lumigan 0.01%, Clinical Trial Description, 2021

Table 66: Bimatoprost SR, Clinical Trial Description, 2021

Table 67: Comparison of emerging drugs under development

Table 68: PDP–716, Clinical Trial Description, 2021

Table 69: PRO-122, Clinical Trial Description, 2021

Table 70: Brinzolamide Ophthalmic Suspension 1%, Clinical Trial Description, 2021

Table 71: DE-130A, Clinical Trial Description, 2021

Table 72: DE-126, Clinical Trial Description, 2021

Table 73: NCX 470, Clinical Trial Description, 2021

Table 74: SYL040012 (bamosiran), Clinical Trial Description, 2021

Table 75: ENV515, Clinical Trial Description, 2021

Table 76: Nyxol, Clinical Trial Description, 2021

Table 77: K-232, Clinical Trial Description, 2021

Table 78: POLAT-001, Clinical Trial Description, 2021

Table 79: Market Size of Glaucoma in the 7MM in USD Million (2018–2030)

Table 80: Market Size of Glaucoma by therapies in the 7MM, in USD Million (2018–2030)

Table 81: Currently Prescribed Classes and their Side-Effects

Table 82: Key Market Forecast Assumptions for Vyzulta

Table 83: Key Market Forecast Assumptions for Rhopressa/Rhokiinsa

Table 84: Key Market Forecast Assumptions for Roclanda/Rocklatan

Table 85: Key Market Forecast Assumptions for Xelpros

Table 86: Key Market Forecast Assumptions for DURYSTA (bimatoprost implant)

Table 87: Key Market Forecast Assumptions for EYBELIS/Omidenepag isopropyl/DE-117

Table 88: Key Market Forecast Assumptions for PRO-122

Table 89: Key Market Forecast Assumptions for PDP-716

Table 90: Key Market Forecast Assumptions for DE-130A

Table 91: Key Market Forecast Assumptions for Sepetaprost (DE-126/ONO-9054)

Table 92: Key Market Forecast Assumptions for NCX 470

Table 93: Key Market Forecast Assumptions for Nyxol

Table 94: Key Market Forecast Assumptions for K-232 (Ripasudil/Brimonidine)

Table 95: Market Size of Glaucoma by therapies in the US, in USD Million (2018–2030)

Table 96: Germany Market Size of Glaucoma in USD Million (2018–2030)

Table 97: Market Size of Glaucoma by therapies in Germany, in USD Million (2018–2030)

Table 98: France Market Size of Glaucoma in USD Million (2018–2030)

Table 99: Market Size of Glaucoma by therapies in France, in USD Million (2018–2030)

Table 100:  Italy Market Size of Glaucoma in USD Million (2018–2030)

Table 101: Market Size of Glaucoma by therapies in Italy, in USD Million (2018–2030)

Table 102: Spain Market Size of Glaucoma in USD Million (2018–2030)

Table 103: Market Size of Glaucoma by therapies in Spain, in USD Million (2018–2030)

Table 104: The UK Market Size of Glaucoma in USD Million (2018–2030)

Table 105: Market Size of Glaucoma by therapies in the UK, in USD Million (2018–2030)

Table 106: Japan Market Size of Glaucoma in USD Million (2018–2030)

Table 107: Market Size of Glaucoma by therapies in Japan, in USD Million (2018–2030)

List of Figures

Figure 1: Classification of Glaucoma

Figure 2: Classification of Open-Angle Glaucoma

Figure 3: Glaucoma classification and subtypes.

Figure 4: Symptoms of Open-Angle Glaucoma

Figure 5: Symptoms of Closed-angle Glaucoma

Figure 6: Risk Factors Associated with POAG

Figure 7: Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by an MYOC mutation

Figure 8: Diagnosis of Glaucoma

Figure 9: Glaucoma Assessment (Optic Nerve)

Figure 10: Clinical findings that define patients seen with Angle-Closure disease

Figure 11: Evaluation of a glaucoma suspect (open-angle glaucoma)

Figure 12: Evaluation of a glaucoma suspect (angle-closure disease)

Figure 13: Treatment of primary open-angle glaucoma: Medical treatment

Figure 14: Treatment Algorithm for Open-Angle Glaucoma

Figure 15: Treatment of primary OAG: Medical treatment

Figure 16: Treatment Algorithm for Open-angle Glaucoma

Figure 17: Total Diagnosed Prevalence of Glaucoma in the 7MM (2018–2030)

Figure 18: Total Diagnosed Prevalence of Glaucoma in the United States (2018–2030)

Figure 19: Type-specific Diagnosed Prevalent Population of Glaucoma in the US (2018–2030)

Figure 20: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2018–2030)

Figure 21: Age-Specific Diagnosed Prevalence of Glaucoma in the United States (2018–2030)

Figure 22: Type-specific Diagnosed Prevalence of Open-angle Glaucoma in the United States (2018–2030)

Figure 23: Total Diagnosed Prevalence of Glaucoma in Germany (2018–2030)

Figure 24: Type-specific Diagnosed Prevalent Population of Glaucoma in Germany (2018–2030)

Figure 25: Gender-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)

Figure 26: Age-specific Diagnosed Prevalence of Glaucoma in Germany (2018–2030)

Figure 27: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Germany (2018–2030)

Figure 28: Total Diagnosed Prevalence of Glaucoma in France (2018–2030)

Figure 29: Type-specific Diagnosed Prevalent Population of Glaucoma in France (2018–2030)

Figure 30: Gender-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)

Figure 31: Age-specific Diagnosed Prevalence of Glaucoma in France (2018–2030)

Figure 32: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in France (2018–2030)

Figure 33: Total Diagnosed Prevalence of Glaucoma in Italy (2018–2030)

Figure 34: Type-specific Diagnosed Prevalent Population of Glaucoma in Italy (2018–2030)

Figure 35: Gender-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)

Figure 36: Age-specific Diagnosed Prevalence of Glaucoma in Italy (2018–2030)

Figure 37: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Italy (2018–2030)

Figure 38: Total Diagnosed Prevalence of Glaucoma in Spain (2018–2030)

Figure 39: Type-specific Diagnosed Prevalent Population of Glaucoma in Spain (2018–2030)

Figure 40: Gender-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)

Figure 41: Age-specific Diagnosed Prevalence of Glaucoma in Spain (2018–2030)

Figure 42: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Spain (2018–2030)

Figure 43: Total Diagnosed Prevalence of Glaucoma in the UK (2018–2030)

Figure 44: Type-specific Diagnosed Prevalent Population of Glaucoma in the UK (2018–2030)

Figure 45: Gender-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)

Figure 46: Age-specific Diagnosed Prevalence of Glaucoma in the UK (2018–2030)

Figure 47: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in the UK (2018–2030)

Figure 48: Total Diagnosed Prevalence of Glaucoma in Japan (2018–2030)

Figure 49: Type-specific Diagnosed Prevalent Population of Glaucoma in Japan (2018–2030)

Figure 50: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)

Figure 51: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2018–2030)

Figure 52: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2018–2030)

Figure 53: Market Size of Glaucoma in the 7MM in USD Million (2018–2030)

Figure 54: Seven Major Market Size of Glaucoma by Therapies in the 7MM, in USD Million (2018–2030)

Figure 55: Market Size of Glaucoma in the US, USD Millions (2018–2030)

Figure 56: Market Size of Glaucoma in the US, USD Millions (2018–2030)

Figure 57: Market Size of Glaucoma by therapies in the United States, in USD Million (2018–2030)

Figure 58: Market Size of Glaucoma in Germany, USD Million (2018–2030)

Figure 59: Germany Market Size of Glaucoma by Therapies in USD Million (2018–2030)

Figure 60: Market Size of Glaucoma in France, USD Million (2018–2030)

Figure 61: France Market Size of Glaucoma by Therapies in USD Million (2018–2030)

Figure 62: Market Size of Glaucoma in Italy, USD Million (2018–2030)

Figure 63: Italy Market Size of Glaucoma by Therapies in USD Million (2018–2030)

Figure 64: Market Size of Glaucoma in Spain, USD Million (2018–2030)

Figure 65: Market Size of Glaucoma by therapies in Spain in USD Million (2018–2030)

Figure 66: Market Size of Glaucoma in the United Kingdom, USD Million (2018–2030)

Figure 67: UK Market Size of Glaucoma by Therapies in USD Million (2018–2030)

Figure 68: Market Size of Glaucoma in Japan, USD Million (2018–2030)

Figure 69: Japan Market Size of Glaucoma by Therapies in USD Million (2018–2030)

• Aerie Pharmaceuticals

• Aerie Pharmaceuticals

• Sun Pharma Advanced Research Company Limited

• Santen Pharmaceutical/Ube Industries

• Bausch and Lomb

• Santen Pharmaceutical Co., Ltd.

• D.Western Therapeutics Institute (DWTI)/Kowa LTD.

• Alcon Research

• Merck Sharp & Dohme Corp.

• Novartis/Alcon Research

• Alcon Research, a Novartis company

• Allergan

• Allergan

• Senju Pharmaceuticals

• Senju Pharmaceuticals

• Sun Pharma Advanced Research Company Limited (SPARC)

• Laboratorios Sophia S.A de C.V.

• Perrigo Company

• Santen Pharmaceutical

• Santen Inc./Ono Pharmaceutical

• Nicox Ophthalmics

• Sylentis

• Envisia Therapeutics

• Ocuphire Pharma

  • Tags:
  • Glaucoma market
  • Glaucoma market research
  • Glaucoma market insight
  • Glaucoma market trends
  • Glaucoma market forecast
  • Glaucoma market share
  • Glaucoma pipeline drugs
  • Glaucoma treatment algorithm
  • Glaucoma drugs
  • Glaucoma sales forecasting
  • Glaucoma market size
  • Glaucoma disease
  • Glaucoma epidemiology
  • Glaucoma

Forward to Friend

Need A Quote